Sign in

You're signed outSign in or to get full access.

Debarati Sen

Director at NORTECH SYSTEMS
Board

About Debarati Sen

Debarati Sen (age 56) is an independent director of Nortech Systems (NSYS), serving since 2024. She is Group President at HMTX Industries and previously held multiple senior leadership roles at 3M, including President of several divisions and Managing Director & CEO of 3M India Ltd; she holds a B.E. in Electronics (NIT Bhopal) and an MBA in Marketing (XLRI Jamshedpur) .

Past Roles

OrganizationRoleTenureCommittees/Impact
3MPresident, Home Improvement & Consumer Well-beingJun–Dec 2023Senior P&L leadership
3MPresident, Construction & Home Improvement DivisionApr 2022–Jun 2023Commercial leadership
3MPresident, Abrasive Systems DivisionJun 2019–Apr 2022Industrial portfolio oversight
3M India Ltd (NSE/BSE: 3MINDIA)Managing Director & CEO, 3M India RegionJun 2016–Jun 2019Led listed subsidiary; regulated-market experience

External Roles

OrganizationRoleTenureNotes
HMTX Industries Inc.Group PresidentCurrentOperating executive role
OneSource Specialty PharmaDirectorCurrentBoard service (company type not specified)
Women’s Foundation of MinnesotaTreasurer; Trustee; Chair, Financial Leadership CommitteeCurrentNon-profit finance leadership
Global Women’s Network, Carlson School of Management (UMN)Senior Advisory Board MemberCurrentAcademic advisory role

Board Governance

  • Committees: Audit Committee (member); Science and Technology Committee (member) .
  • Independence: Board determined Sen is independent under NASDAQ rules .
  • Financial expertise: Designated “audit committee financial expert” (with Stacy Kruse) under SEC regulations .
  • Attendance: Board met 5 times in the last fiscal year; all directors attended all Board meetings; all committee members attended all their meetings .
  • Controlled company context: NSYS is a “controlled company” under NASDAQ rules (Kunin family control); Audit Committee remains fully independent; Compensation and Nominating committees maintain majority independence even under controlled-company exemptions .
CommitteeChairMeetings (FY)Sen MembershipAttendance (Sen)
AuditStacy A. Kruse4Member 100% (all members attended)
Compensation & TalentJose A. Peris5Not listed as member n/a
Nominating & Corporate GovernanceAmy S. Fredregill4Not listed as member n/a
Science & TechnologyRyan P. McManus4Member 100% (all members attended)

Fixed Compensation

DirectorYearCash Fees ($)Notes
Debarati Sen202423,500 Mid-year commencement; fee schedule below
2024 Fee ScheduleAmount ($)
Non-employee director annual retainer36,000
Chair of the Board27,000
Audit Committee Chair14,000
Compensation & Talent Committee Chair10,000
Nominating & Corporate Governance Committee Chair8,000
Science & Technology Committee Chair8,000
Audit Committee member (non-chair)7,000
Compensation & Talent member (non-chair)5,000
Nominating & Corporate Governance member (non-chair)4,000
Science & Technology member (non-chair)4,000

Performance Compensation

DirectorGrant DateInstrumentShares/UnitsGrant Fair Value ($)VestingPerformance Metrics
Debarati SenMay 20, 2024RSUs3,255 36,000 Vests equally on 1st and 2nd anniversary; one share per vested RSU issued within 60 days None disclosed (time-based RSU)

Other directors received 1,981 RSUs on May 20, 2024 with the same vesting cadence .

Other Directorships & Interlocks

CompanyPublic/PrivateRoleInterlock/Conflict Notes
OneSource Specialty PharmaNot specifiedDirectorNo NSYS-related transactions disclosed
3M India Ltd (3MINDIA)PublicFormer MD & CEOPast operating role; no current interlock with NSYS disclosed

Expertise & Qualifications

  • Electronics and manufacturing leadership across industrial and consumer verticals; overseas listed-company leadership (3M India) .
  • Financial oversight and audit proficiency (SEC-designated audit committee financial expert) .
  • Non-profit and academic governance roles indicating stakeholder engagement and financial stewardship .

Equity Ownership

HolderBeneficial Ownership (Shares)% of ClassInstruments (60-day window)Notes
Debarati Sen3,255 <1% 3,255 shares issuable upon RSU vesting/exercisable options within 60 days of Mar 19, 2025 Shares outstanding: 2,760,993 as of Mar 19, 2025
  • Pledging/hedging: No pledging disclosures identified for Sen in the proxy’s ownership and related-party sections .

Governance Assessment

  • Board effectiveness: Sen strengthens financial oversight (audit committee) and cyber/technology risk governance (Science & Technology), with SEC-recognized audit expertise—a positive signal for investor confidence .
  • Independence and attendance: Independent under NASDAQ rules; perfect attendance noted across Board and committee meetings—supports engagement quality .
  • Compensation alignment: Director pay mix leans time-based RSUs alongside modest cash fees; no performance-linked metrics—typical for board compensation but implies alignment via equity without pay-for-performance levers .
  • Shareholder feedback: 2024 Say-on-Pay passed with 1,576,442 For vs. 22,124 Against; board slate including Sen elected with strong support (e.g., 1,583,656 For for Sen) .
  • RED FLAGS:
    • Section 16 timeliness: Sen filed Form 3 and Form 4 late on July 12, 2024 (for RSU grant May 20, 2024); administrative lapse but limited materiality—monitor for recurrence .
    • Controlled company status: Majority voting power held by Kunin family; mitigated by independent Audit Committee and majority-independent Board composition post-2025 slate .

Appendix: Insider Filings Summary (Section 16)

FilingEventFiling DateNotes
Form 3Became director (May 15, 2024)Jul 12, 2024Filed late per proxy disclosure
Form 4RSU grant (May 20, 2024)Jul 12, 2024Filed late per proxy disclosure

Notes on Related-Party Transactions

  • No transactions disclosed involving Debarati Sen personally. Related-party transactions disclosed involve Chair David Kunin (Abilitech, Marpe Technologies) and are overseen by the Audit Committee under a formal policy .